Compositions and methods for treatment of non-hodgkins lymphoma

Patent metadata

Field	Value
Publication number	US-10166276-B2
Application number	US-201414329092-A
Country	US
Kind code	B2
Filing date	Jul 11, 2014
Priority date	May 2, 2006
Publication date	Jan 1, 2019
Grant date	Jan 1, 2019

Abstract

The present invention provides recombinant peptides comprising a B cell receptor (BCR) or a fragment thereof, nucleotide molecules encoding same, and vaccines and vectors comprising same; and methods of treating, inducing an immune response against, inducing a regression of, and suppressing a formation of a lymphoma, comprising administering same. The present invention also provides methods of inducing a humoral immune response in an animal against an antigen, comprising administering to the animal a fusion peptide comprising an LLO protein or fragment thereof fused to the antigen.

First claim

What is claimed:

1. A method of inducing an immune response against a B cell lymphoma in a subject, comprising administering a pharmaceutical composition comprising a fusion polypeptide comprising a fragment of a listeriolysin O (LLO) protein and an antigen, wherein said fragment of an LLO protein is chemically conjugated to said antigen, wherein said antigen is a fragment of a B cell receptor (BCR) comprising the idiotype of said BCR, and wherein said fragment of an LLO protein is an N-terminal fragment comprising the amino acid sequence set forth in SEQ ID NO: 25 or an N-terminal LLO-detox fragment comprising the amino acid sequence set forth in SEQ ID NO: 41.

2. The method of claim 1 , wherein said fragment of a BCR is a single chain fragment of the variable regions (scFV) of said BCR.

3. The method of claim 1 , wherein said fragment of a BCR is a 38C13 idiotype of said BCR.

4. The method of claim 3 , wherein said 38C13 idiotype comprises SEQ ID NO: 48.

5. The method of claim 1 , wherein said B cell lymphoma comprises said idiotype.

6. A recombinant Listeria, comprising said fusion polypeptide of claim 1 .

7. A method of inducing an immune response against a B cell lymphoma in a subject, wherein said method comprises administering an isolated polypeptide vaccine mixture, comprising a fragment of a listeriolysin (LLO) protein and an antigen, wherein said antigen is either
a. a B cell receptor (BCR); or
b. a fragment of a BCR comprising the idiotype of said BCR;

and wherein said fragment of an LLO protein is an N-terminal fragment comprising the amino acid sequence set forth in SEQ ID NO: 25 or an N-terminal LLO-detox fragment comprising the amino acid sequence set forth in SEQ ID NO: 41.

8. The method of claim 7 , wherein said fragment of a BCR is a single chain fragment of the variable regions (scFV) of said BCR.

9. The method of claim 7 , wherein said fragment of a BCR is a 38C13 idiotype of said BCR.

10. The method of claim 9 , wherein said 38C13 idiotype comprises SEQ ID NO: 48.

11. The method of claim 7 , wherein said B cell lymphoma comprises said idiotype.

12. The method of claim 1 , wherein said immune response treats a B cell lymphoma in said subject.

13. The method of claim 7 , wherein said immune response treats a B cell lymphoma in said subject.

14. The method of claim 1 , wherein said immune response induces the regression of a B cell lymphoma in said subject.

15. The method of claim 7 , wherein said immune response induces the regression of a B cell lymphoma in said subject.

16. The method of claim 1 , wherein said immune response overcomes immune tolerance to a B cell lymphoma in said subject.

17. The method of claim 7 , wherein said immune response overcomes immune tolerance a B cell lymphoma in said subject.

18. The method of claim 1 , wherein said immune response reduces the incidence of relapse of a B cell lymphoma in said subject.

19. The method of claim 7 , wherein said immune response reduces the incidence of relapse of a B cell lymphoma in said subject.

20. The method of claim 1 , wherein said immune response suppresses a formation of a B cell lymphoma in said subject.

21. The method of claim 7 , wherein said immune response suppresses a formation of a B cell lymphoma in said subject.

22. The method of claim 1 , wherein said immune response reduces remission of a residual B cell lymphoma disease in said subject.

23. The method of claim 7 , wherein said immune response reduces remission of a residual B cell lymphoma disease in said subject.

24. The method of claim 1 , wherein said immune response induces a humoral response against a B cell lymphoma in said subject.

25. The method of claim 1 , further comprising inducing an antiserum.

26. A method of producing a monoclonal antibody, comprising inducing a humoral immune response in an animal according to the method of claim 1 .

27. The method of claim 7 , wherein said immune response induces humoral response against a B cell lymphoma in said subject.

28. The method of claim 7 , further comprising inducing an antiserum.

29. A method of producing a monoclonal antibody, comprising inducing a humoral immune response in an animal according to the method of claim 7 .

Assignees

• Univ Pennsylvania
• The Trustees Of The Univ Of Philadelphia

Inventors

• Paterson Yvonne
• Neeson Paul

Classifications

• C07K16/1285

  from Corynebacterium (G) · CPC title

• C07K16/4208

  against an idiotypic determinant on Ig · CPC title

• C07K14/195 Primary

  from bacteria · CPC title

• C07K16/00

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title

• C07K14/70503

  Immunoglobulin superfamily · CPC title